A meta-analysis demonstrated that ICIs are less effective than docetaxel when used as a second- or third-line therapy, resulting in inferior overall survival rates in NSCLC patients with EGFR-positive mutations [4]. Here, EGFR is linked to non-small cell lung carcinoma.